Clinical Trial: Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer

U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07068542) titled 'Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer' on May 14.

Brief Summary: This study is a multi-center, phase II clinical trial, primarily enrolling patients with unresectable, locally advanced or metastatic undifferentiated thyroid cancer (ATC) or radioiodine-refractory differentiated thyroid cancer (RAIR-DTC). Eligible patients will receive treatment with Sacituzumab tirumotecan combined with tislelizumab until disease progression or intolerability occurs. The effectiveness and safety will be evaluated.

Study Start Date: Aug. 01

Study Type: INTERVENTIONAL

Condition: Advanced Thyroid Carcinoma Ra...